Investors do not like surprises with negative overtones, so they reacted badly when Amgen announced last Tuesday that it was conducting a new study to compare a 240 mg dose of its KRAS-targeted lung cancer pill, sotorasib, against the 960 mg dose that is now under review by the Food and Drug Administration.
Amgen’s stock price fell 6% last week, the most among all the large-cap drug makers.
About the Author Reprints
